Evaluation of CT perfusion as biomarker for chemotherapy response in pancreatic ductal adenocarcinoma.

Congress:

ECR 2021

Poster Number:

C-14092

Type:

Scientific Exhibit

Keywords:

Abdomen, Contrast agents, Pancreas, CT-Quantitative, Experimental investigations, Treatment effects, Cancer

Authors:

T. H. Perik, E. Van Geenen, E. J. Smit, L. A. A. Brosens, M. W. J. Stommel, E. C. Gootjes, K. J. H. M. Van Laarhoven, H. Huisman, J. J. Hermans; Nijmegen/NL

DOI:

10.26044/ecr2021/C-14092

DOI-Link:

https://dx.doi.org/10.26044/ecr2021/C-14092

References

[1] C. G. Willett, B. G. Czito, J. C. Bendell, and D. P. Ryan, “Locally advanced pancreatic cancer,” J. Clin. Oncol., vol. 23, no. 20, pp. 4538–4544, 2005, doi: 10.1200/JCO.2005.23.911.

[2] F. Petrelli et al., “FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: A meta-analytical review of published studies,” Pancreas, vol. 44, no. 4, pp. 515–521, 2015, doi: 10.1097/MPA.0000000000000314.

[3] T. Conroy et al., “FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer,” N. Engl. J. Med., vol. 364, no. 19, pp. 1817–1825, 2011, doi: 10.1056/nejmoa1011923.

[4] C. Cassinotto, A. Sa-Cunha, and H. Trillaud, “Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer,” Diagn. Interv. Imaging, vol. 97, no. 12, pp. 1225–1232, 2016, doi: 10.1016/j.diii.2016.07.011.

[5] M. H. G. Katz et al., “Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators,” Cancer, vol. 118, no. 23, pp. 5749–5756, 2012, doi: 10.1002/cncr.27636.

[6] A. Hamdy et al., “Perfusion CT to assess response to neoadjuvant chemotherapy and radiation therapy in pancreatic ductal adenocarcinoma: Initial experience,” Radiology, vol. 292, no. 3, pp. 628–635, 2019, doi: 10.1148/radiol.2019182561.

[7] S. Schneeweiß et al., “CT-perfusion measurements in pancreatic carcinoma with different kinetic models: Is there a chance for tumour grading based on functional parameters?,” Cancer Imaging, vol. 16, no. 1, pp. 1–8, 2016, doi: 10.1186/s40644-016-0100-6.

Fig 1: Diagram depicting the interleaved CT perfusion protocol. All bars represent a...

Fig 2: Animated GIF: An example of dynamic contrast-enhanced acquisitions in the...

Fig 3: Size changes for all patients on the left using RECIST-criteria (Responder:...

Fig 4: Example of TIC of a non-responder at baseline (BF=23,4 ml/100g/min; Max...

Fig 5: Example of TIC of a responder at baseline (BF=20.2 ml/100g/min; Max...

Fig 6: Percentual change in blood flow (BF) after chemotherapy in responders [R] and...

Fig 7: Percentual change in maximum enhancement after chemotherapy in responders [R]...